rev: April 14, 2001

HOME (index page)

Return (alphabetical antibody index page)

Return  (neurohistology ab index page)


ANTIBODIES  

(anti-Human and others as indicated)

RDI Division of Fitzgerald Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, histochemistry, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.

Human Ubiquitin Carboxyl-terminal Hydrolase L1 N-terminal Antiserum

Product:               Ubiquitin Carboxyl-Terminal Hydrolase L1 N-terminal Antiserum

Cat No:                RDI-UBIQL1abG   $315.00/0.25ml

Host:                   Goat

Clone:                 Polyclonal

Immunogen:          Synthetic Peptide: 46 NFRKKQIEELKGQEVSPK63

Form:                  Whole serum

Concentration:      N/A

Supplied as:          1 ml vials

Titer:                   Reported working dilution using neat serum:*

v    ELISA using immunizing peptide: 1:71,350

v    IHC using formalin-fixed, paraffin-embedded sections: N/D

v    IHC using paraformaldehyde-fixed, frozen sections: N/D

v    Western blots:  1:2,000

Specificity:           Amino acid sequence 46-63 of human ubiquitin carboxyl-terminal hydrolase L1 protein.

 Preservative:                 0.1% Sodium Azide

                          (no azide  cat#RDI-UBIQL1abgX  $938.0/1ml)

Storage:               Short term: Refrigerate at 4º C

Long term: Freeze at -20º C.

 FOR RESEARCH AND MANUFACTURING USE ONLY

* Various assay conditions require that the optimum working concentrations be determined by serial dilutions of this product.

Product: Human Ubiquitin Carboxyl-terminal Hydrolase L1 N-terminal Antiserum

 Ubiquitin carboxyl-terminal hydrolase L1 (UCH –L1) is one of the most abundant proteins in the brain and represents 1-2% of total soluble brain proteins.  UCH-L1 activity is thought to cleave polymeric ubiquitin to monomers and to hydrolyze bonds between ubiquitin-protein conjugatges to regenerate ubiquitin monomers.   In many degenerative diseases, ubiquitin has been identified as a component of several inclusion bodies and certain of these are associated with UCH-L1 activity.  One such inclusion is the Lewy body of Parkinson’s disease.  Since a polymorphism has been detected in the UCH-L1 gene, it is suspected to have a role is some forms of Parkinson’s disease.

 A goat antiserum to a synthetic peptide that corresponds to amino acids 46-63 of the N-terminus of the human UCH-L1 is currently available. This antiserum has been shown to be immunoreactive with the unconjugated immunizing peptide by ELISA. It also labels a 27 kD protein in western blots.  This antibody should be a valuable tool for scientists working to understand the role of UCH-L1 in Parkinson’s disease.

This antiserum was produced using proprietary methodology whereby the peptide is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the peptide.  Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification.  A control immune serum from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no. RDI-UBIQL1-CPX) which can be used to neutralize immunoreactivity.

 Ubiquitin Carboxyl-Terminal Hydrolase L1 N-terminal Antiserum 

Western blot analysis of normal aged control brains using UCH-L1 antiserum at 1:2,000 dilution.  UCH-L1 is observed to have a molecular weight of 27 kD.

  For Research Use Only 

See other antibodies to ubiquitin at: 

http://www.researchd.com/absort.htm

RDI Division of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049

USA

phone (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266

EMAIL:antibodies@fitzgerald-fii.com

RETURN (neurohistology ab page)

Return (alphabetical antibody index page)